IGC Pharma Inc

IGS1

Company Profile

  • Business description

    IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer’s disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles.

  • Contact

    10224 Falls Road
    PotomacMD20854
    USA

    T: +1 301 983-0998

    E: [email protected]

    https://www.igcinc.us

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2027

    Employees

    70

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,927.75152.99-1.89%
DAX 4024,802.78661.03-2.60%
Dow JONES (US)48,734.05363.01-0.74%
FTSE 10010,346.34106.34-1.02%
HKSE22,410.80430.82-1.89%
NASDAQ22,986.05893.15-3.74%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5007,011.02164.81-2.30%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers